Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
äŒæ¥ã³ãŒãINDV
äŒç€ŸåIndivior PLC
äžå Žæ¥Dec 24, 2014
æé«çµå¶è²¬ä»»è
ãCEOãCiaffoni (Joseph J)
åŸæ¥å¡æ°1030
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 24
æ¬ç€Ÿæåšå°234 Bath Road
éœåžSLOUGH
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited Kingdom
éµäŸ¿çªå·SL1 4EE
é»è©±çªå·448043791090
ãŠã§ããµã€ãhttps://www.indivior.com/en
äŒæ¥ã³ãŒãINDV
äžå Žæ¥Dec 24, 2014
æé«çµå¶è²¬ä»»è
ãCEOãCiaffoni (Joseph J)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã